Nemec Sarah purchased $2K of BOLT

Bolt Biotherapeutics completed its merger with Prana Therapies on October 23, 2026, issuing shares to Prana equityholders. Bolt also secured a $120 million private placement, with potential for $60 million more from warrant exercises. The merger included stockholder support agreements, 180-day lock-ups, and a $4.5 million lease termination payment.

Bolt Biotherapeutics, Inc. (BOLT) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Bolt Biotherapeutics Announces Acquisition of Prana Therapies and $120 Million Concurrent Private Placement to Advance PRA-216 in Multiple High-Value Inflammatory Indications • Transactions position the company to advance Prana’s pipeline of next-generation, half-lif

Bolt Biotherapeutics (BOLT) acquired Prana Therapies via a stock-for-stock deal, exchanging shares for Prana's equity. Bolt also secured $120 million in a private placement, issuing Series D preferred stock and warrants. The funds will support operations into 2028. Prana's co-founder, Sheila Gujrathi, joined Bolt's board as chief strategy officer. BOLT shares closed at $4.19 on Nasdaq.

Bolt Biotherapeutics (BOLT) acquired Prana Therapies in a reverse merger, raising $120M with potential for $60M more. Post-merger, Prana shareholders own 51.7% of Bolt. The combined company will advance Prana's INSPIRE platform, with Phase 2 data expected in Q2 2027. Sheila Gujrathi, Prana's co-founder, joins Bolt's board.

Bolt Biotherapeutics (BOLT) acquired Prana via a reverse merger and secured $120M in private placement, with up to $60M more via warrants. The deal extends Bolt's cash runway into 2028 and focuses its pipeline on Prana's assets, including PRA-216 in Phase 2 trials. Existing Bolt holders own ~6.9% post-transaction.

Bolt Biotherapeutics (BOLT) acquired Prana Therapies, securing $120M in financing, with up to $60M more possible. The deal advances Prana's pipeline, including PRA-216, a bispecific antibody in Phase 2 trials for asthma, COPD, and atopic dermatitis. Data from all trials is expected in Q2 2027. Dr. Sheila Gujrathi, Prana's co-founder, joins Bolt's executive team. The financing is expected to fund operations into 2028.